Oncology & Cancer

Entrectinib gets edge over crizotinib against ROS1+ lung cancer

Crizotinib and entrectinib are both active against ROS1+ non-small cell lung cancer. But which is best? The answer seems easy: Just compare the drugs' clinical trial results. However, not all trials are created equal, and ...

Medical research

Johns Hopkins researchers publish digital health roadmap

In the dizzying swirl of health-related websites, social media and smartphone apps, finding a reliable source of health information can be a challenge. A group of researchers from the Johns Hopkins University schools of medicine ...

Genetics

Genetic cause identified in familial sarcoidosis

Sarcoidosis is a disease in which nodules of immune cells form, primarily in the lungs but also in the skin or in the heart. While the lung symptoms are similar to those of tuberculosis, the etiology of the disease is unknown. ...

Parkinson's & Movement disorders

Parkinson's disease experts devise a roadmap

A recently discovered protein, alpha-synuclein, has become one of the most attractive targets for developing new drugs with the potential to slow down or arrest the progression of Parkinson's disease (PD). Experts in the ...

Alzheimer's disease & dementia

Precision medicine offers a glimmer of hope for Alzheimer's disease

The decadeslong search for effective ways to treat or prevent Alzheimer's disease is littered with failures, leaving 5.7 million Americans already stricken with this form of dementia without a lifeline. The rest of us are ...

Cardiology

Osteoporosis drug may benefit heart health

The osteoporosis drug alendronate was linked with a reduced risk of cardiovascular death, heart attack, and stroke in a Journal of Bone and Mineral Research study of patients with hip fractures. The association was seen for ...

page 1 from 3